Tesaro shares skid low­er as As­traZeneca wows with PhI­II da­ta on PARP drug for ovar­i­an can­cer

As­traZeneca spelled out its im­pres­sive Phase III da­ta for Lyn­parza (ola­parib) pills, which will now line up against Tesaro’s ri­val PARP ni­ra­parib.

Pas­cal So­ri­ot

In a cen­tral, blind­ed re­view the drug achieved a me­di­an pro­gres­sion-free sur­vival rate of 30.2 months in germline BR­CA-mu­tat­ed, plat­inum-sen­si­tive, re­lapsed ovar­i­an can­cer pa­tients ver­sus 5.5 months for the place­bo arm. A sol­id suc­cess for As­traZeneca, which bad­ly needs to con­tin­ue to build up its on­col­o­gy group if CEO Pas­cal So­ri­ot ex­pects to achieve any­thing like the big turn­around he’s been promis­ing in­vestors for years.

The drug al­so achieved a sta­tis­ti­cal­ly sig­nif­i­cant re­sult in de­lay­ing the sec­ond pro­gres­sion or time to death, with the me­di­an rate not reached for Lyn­parza com­pared to 18.4 months for place­bo.

As­traZeneca got a jump on the PARP mar­ket with shaky ear­ly da­ta, which reined in its rev­enue po­ten­tial. The phar­ma gi­ant earned on­ly a bit more than $200 mil­lion on Lyn­parza last year, but ex­pects to in­crease that past the $1 bil­lion block­buster mark as it looks to broad­en its use as a main­te­nance ther­a­py in the US.

Tesaro $TSRO has been aim­ing at a di­rect show­down with As­traZeneca as it winds up for a like­ly near-term ap­proval on ni­ra­parib. Its re­duc­tion in risk com­pares close­ly to ola­parib, with a PFS rate that won’t look as good.

Tesaro’s ni­ra­parib da­ta high­light­ed a clear im­pact for the tar­get­ed drug in a pop­u­la­tion of germline BR­CA mu­ta­tion car­ri­ers, with a me­di­an PFS of 21 months in the drug group com­pared to 5.5 months in the con­trol arm — a 15.5-month ad­van­tage that will not com­pare well with Lyn­parza’s, which beat place­bo by slight­ly more than two years.

Sean Bo­hen

Tesaro’s shares skid­ded down 12.5% on the com­par­i­son. Clo­vis $CLVS, mean­while, which has had prob­lems of its own in de­vel­op­ing its new­ly ap­proved PARP Rubra­ca, saw its shares rise 6.9% as the horse race among all the PARPs looked tighter than ever.

Pfiz­er will look to join this group in the not too dis­tant fu­ture with its own piv­otal da­ta for a PARP — ta­la­zoparib — picked up in the $14 bil­lion Medi­va­tion ac­qui­si­tion.

“With these da­ta, we be­lieve it is very dif­fi­cult to chal­lenge the no­tion that the lead­ing PARPs (ni­ra­parib, ola­parib, ru­ca­parib, ta­la­zoparib) are more sim­i­lar than dif­fer­ent,” summed up Leerink’s Sea­mus Fer­nan­dez. “But fol­low­ing our con­ver­sa­tion with AZN, they are most fo­cused on the safe­ty and tol­er­a­bil­i­ty of ola­parib, which they be­lieve is a key area of dif­fer­en­ti­a­tion vs. ni­ra­parib.”

As­traZeneca R&D chief Sean Bo­hen said:

We are ex­treme­ly pleased with the re­sults from SO­LO-2, which sup­port the po­ten­tial ben­e­fit of LYN­PARZA tablets as a main­te­nance ther­a­py for pa­tients with re­lapsed ovar­i­an can­cer. The tablet for­mu­la­tion may of­fer pa­tients a re­duced pill bur­den for LYN­PARZA and a safe­ty pro­file that is gen­er­al­ly con­sis­tent with pre­vi­ous tri­als. We will work with reg­u­la­to­ry au­thor­i­ties to make LYN­PARZA tablets avail­able to pa­tients as quick­ly as pos­si­ble.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma.

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

We don’t know what the data are yet, but DREAMM-2 falls on the heels of a promising set of data delivered 5 months ago for DREAMM-1. There investigators noted that complete responses among treatment-resistant patients rose to 15% in the extra year’s worth of data to look over, with a median progression-free survival rate of 12 months, up from 7.9 months reported earlier. The median duration of response was 14.3 months.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Smith, Pfizer

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.

Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.

And now they’re really going for it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden.

Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

A rumor that Amgen is closing in on buyout deal for Alexion has sparked a guessing game on just what kind of M&A strategy Amgen is pursuing and how much Alexion is worth.

Mizuho analyst Salim Syed first lent credence to the report out of the Spanish news outlet Intereconomía, which said Amgen is bidding as much as $200 per share. While the source may be questionable, “the concept of this happening doesn’t sound too crazy to me,” he wrote.